journal
MENU ▼
Read by QxMD icon Read
search

Oncologist

journal
https://www.readbyqxmd.com/read/29769386/global-acceptance-of-biosimilars-importance-of-regulatory-consistency-education-and-trust
#1
REVIEW
Eduardo Cazap, Ira Jacobs, Ali McBride, Robert Popovian, Karol Sikora
Globally, biosimilars are expected to have a key role in improving patient access to biological therapies and addressing concerns regarding the escalating cost of health care. Indeed, in Europe, increased use of biologics and reduced drug prices have been observed after the introduction of biosimilars. Recently, several monoclonal antibody biosimilars of anticancer therapies have been approved, and numerous others are in various stages of clinical development. Biosimilars are authorized via a regulatory pathway separate from that used for generic drugs; they are also regulated separately from novel biologics...
May 16, 2018: Oncologist
https://www.readbyqxmd.com/read/29769385/phase-ii-study-of-irinotecan-plus-panitumumab-as-second-line-therapy-for-patients-with-advanced-esophageal-adenocarcinoma
#2
Harry Yoon, Anita Choudhary, Ramla Kosozi, Gurvinder Singh Bali, Ali Zaidi, Ajlan Atasoy, Arlene A Forastiere, Michael K Gibson
LESSON LEARNED: Panitumumab plus irinotecan is not active for the treatment of esophageal adenocarcinoma. BACKGROUND: Esophageal adenocarcinoma (EAC) is a lethal cancer with increasing incidence. Panitumumab (Pa) is a fully humanized IgG2 monoclonal antibody against human EGFR. Cetuximab (Cx) combined with irinotecan (Ir) is active for second-line treatment of colorectal cancer. This phase II study was designed to evaluate Pa plus Ir as second-line therapy for advanced EAC...
May 16, 2018: Oncologist
https://www.readbyqxmd.com/read/29769384/meta-research-on-oncology-trials-a-toolkit-for-researchers-with-limited-resources
#3
Rachel P Riechelmann, Julien PĂ©ron, Bostjan Seruga, Everardo D Saad
"Meta-research" is a discipline that investigates research practices. Meta-research on clinical trials is an attempt to summarize descriptive and methodological features of published or ongoing clinical trials, including aspects of their implementation, design, analysis, reporting, and interpretation. In this type of investigation, the unit of analysis is a primary source of information about a clinical trial (e.g., published reports, study protocols, or abstracts), with meta-research being a second layer of information that summarizes what is known from various primary sources...
May 16, 2018: Oncologist
https://www.readbyqxmd.com/read/29769383/incidence-of-thyroid-function-test-abnormalities-in-patients-receiving-immune-checkpoint-inhibitors-for-cancer-treatment
#4
Nisha Subhash Patel, Anais Oury, Gregory A Daniels, Lyudmila Bazhenova, Sandip Pravin Patel
BACKGROUND: With the advent of immune-checkpoint inhibitor (ICI) therapy (anti-CTLA-4, anti-PD-1), immune-related adverse events such as thyroid function test abnormalities (TFTAs) are common, with a reported incidence range of 2%-15% depending upon the ICI used. The aim of this study is to describe the incidence of TFTAs retrospectively in patients who received ICI therapy. METHODS: A total of 285 patients were reviewed (178 male, 107 female; 16-94 years of age), of whom 218 had no baseline TFTAs, 61 had baseline TFTAs, and 6 had a history of thyroidectomy (excluded)...
May 16, 2018: Oncologist
https://www.readbyqxmd.com/read/29769382/personalized-symptom-goals-and-patient-global-impression-on-clinical-changes-in-advanced-cancer-patients
#5
Sebastiano Mercadante, Claudio Adile, Gaetano Lanzetta, Kyriaki Mystakidou, Marco Maltoni, Luiz Guilherme Soares, Stefano De Santis, Patrizia Ferrera, Marco Valenti, Marta Rosati, Romina Rossi, Andrea Cortegiani, Francesco Masedu, Franco Marinangeli, Federica Aielli
BACKGROUND: The aim of this study was to assess the patients' global impression (PGI) after symptom management, as well as the achievement of personalized symptom goals (PSG). The secondary outcome was to assess related factors. Subjects, Materials, and Methods . Advanced cancer patients admitted to palliative care units rated symptom intensity by using the Edmonton Symptom Assessment Score (ESAS) at admission and then after 1 week. For each symptom, patient-reported PGI and PSG, as well as the rate of PSG response, were evaluated...
May 16, 2018: Oncologist
https://www.readbyqxmd.com/read/29739898/eml4-alk-rearrangement-and-its-therapeutic-implications-in-inflammatory-myofibroblastic-tumors
#6
Fernando Vargas-Madueno, Edwin Gould, Raul Valor, Nhu Ngo, Linsheng Zhang, Miguel A Villalona-Calero
With the advent of precision medicine, medical oncology is undergoing a transcendental change. These molecular studies have allowed us to learn about potential targeted therapies for patients with advanced cancers. Perhaps the best-known example of success in precision medicine is chronic myeloid leukemia and its response to tyrosine kinase inhibitors targeting the BCR-ABL kinase. Since that original discovery, the role of molecular therapeutics has expanded, and it now presents us with treatment options for common malignancies and rare atypical tumors...
May 8, 2018: Oncologist
https://www.readbyqxmd.com/read/29739897/cluster-analysis-demonstrates-the-need-to-individualize-care-for-cancer-survivors
#7
Belle H de Rooij, Elyse R Park, Giselle K Perez, Julia Rabin, Katharine M Quain, Don S Dizon, Kathryn E Post, Garrett M Chinn, Allison L McDonough, Rachel B Jimenez, Lonneke V van de Poll-Franse, Jeffrey Peppercorn
BACKGROUND: In efforts to inform clinical screening and development of survivorship care services, we sought to characterize patterns of health care needs among cancer survivors by (a) identifying and characterizing subgroups based on self-reported health care needs and (b) assessing sociodemographic, clinical, and psychosocial factors associated with these subgroups. METHODS: We conducted a cross-sectional self-administered survey among patients presenting for routine follow-up care for early-stage cancer at our academic medical center...
May 8, 2018: Oncologist
https://www.readbyqxmd.com/read/29739896/quantitative-proteomics-analysis-of-sporadic-medullary-thyroid-cancer-reveals-fn1-as-a-potential-novel-candidate-prognostic-biomarker
#8
Shaohua Zhan, Jinming Li, Tianxiao Wang, Wei Ge
BACKGROUND: Sporadic medullary thyroid cancer (MTC) is a rare neuroendocrine tumor. Currently, although the diagnosis of sporadic MTC is relatively simple, the need to discover novel candidate prognostic biomarkers for sporadic MTC and investigate the underlying mechanism involved in this rare disease is urgent. MATERIALS AND METHODS: We employed tandem mass tag-based liquid chromatography-mass spectrometry to identify and analyze differentially expressed proteins (DEPs) in sporadic MTC...
May 8, 2018: Oncologist
https://www.readbyqxmd.com/read/29739895/long-term-survival-rates-of-patients-with-stage-iii-iv-hodgkin-lymphoma-according-to-age-sex-race-and-socioeconomic-status-1984-2013
#9
Yushi Li, Huanhuan Sun, Yan Yan, Tiantian Sun, Shuncong Wang, Haiqing Ma
BACKGROUND: Long-term survival rates for patients with stage III-IV Hodgkin lymphoma, or advanced Hodgkin lymphoma (aHL), have increased substantially since the 1960s. Because large-scale research of aHL is rare, we aimed to demonstrate the differences in incidence and survival of aHL according to four patient variables in recent decades, with a focus on the outcomes of treatment of aHL and the advancement of public health care. MATERIALS AND METHODS: Data on aHL cases diagnosed during 1984-2013 were extracted from the Surveillance, Epidemiology, and End Results Program database...
May 8, 2018: Oncologist
https://www.readbyqxmd.com/read/29739894/interpretation-of-results-from-under-accruing-studies
#10
Sasha Kravets, Suzanne E Dahlberg
No abstract text is available yet for this article.
May 8, 2018: Oncologist
https://www.readbyqxmd.com/read/29739893/trifluridine-tipiracil-tas-102-in-refractory-metastatic-colorectal-cancer-a-multicenter-register-in-the-frame-of-the-italian-compassionate-use-program
#11
Chiara Cremolini, Daniele Rossini, Erika Martinelli, Filippo Pietrantonio, Sara Lonardi, Silvia Noventa, Emiliano Tamburini, Giovanni Luca Frassineti, Stefania Mosconi, Federico Nichetti, Sabina Murgioni, Teresa Troiani, Beatrice Borelli, Gemma Zucchelli, Alessandro Dal Maso, Vincenzo Sforza, Gianluca Masi, Carlotta Antoniotti, Maria Di Bartolomeo, Rosalba Miceli, Fortunato Ciardiello, Alfredo Falcone
BACKGROUND: TAS-102 is indicated for patients with metastatic colorectal cancer (mCRC) previously treated with, or not considered candidates for, available therapies. Given the complete inefficacy in half of patients, the lack of predictive factors, the palliative setting, and the financial and clinical toxicity, optimizing the cost-benefit ratio is crucial. The "ColonLife" nomogram allows an estimate of the 12-week life expectancy of patients with refractory mCRC. MATERIALS AND METHODS: We collected data from patients treated at eight Italian centers in the compassionate use program...
May 8, 2018: Oncologist
https://www.readbyqxmd.com/read/29728471/assessing-the-clinical-utility-of-computed-tomography-based-radiomics
#12
Julia Lai-Kwon, Shankar Siva, Jeremy Lewin
No abstract text is available yet for this article.
May 4, 2018: Oncologist
https://www.readbyqxmd.com/read/29728470/can-we-hang-our-hats-on-one-percent
#13
Nathalie LeVasseur, Karen A Gelmon
No abstract text is available yet for this article.
May 4, 2018: Oncologist
https://www.readbyqxmd.com/read/29728469/in-the-patient-s-shoes
#14
Ana Lucia Coradazzi
No abstract text is available yet for this article.
May 4, 2018: Oncologist
https://www.readbyqxmd.com/read/29728468/esophageal-metal-stents-with-concurrent-chemoradiation-therapy-for-locally-advanced-esophageal-cancer-safe-or-not
#15
Yueh-Feng Lu, Chen-Shuan Chung, Chao-Yu Liu, Pei-Wei Shueng, Le-Jung Wu, Chen-Xiong Hsu, Deng-Yu Kuo, Pei-Yu Hou, Hsiu-Ling Chou, Ka-I Leong, Cheng-Hung How, San-Fang Chou, Li-Ying Wang, Chen-Hsi Hsieh
BACKGROUND: The purpose of this study was to review the risks and benefits of concurrent chemoradiation therapy (CCRT) with esophageal self-expandable metal stents (SEMS) for the treatment of locally advanced esophageal cancer. MATERIALS AND METHODS: Between January 2014 and December 2016, the data from 46 locally advanced esophageal cancer patients who received CCRT at our institution were retrospectively reviewed. Eight patients who received CCRT concomitant with SEMS placement (SEMS plus CCRT group) and thirty-eight patients who received CCRT without SEMS placement (CCRT group) were identified...
May 4, 2018: Oncologist
https://www.readbyqxmd.com/read/29728467/predictors-of-location-of-death-for-children-with-cancer-enrolled-on-a-palliative-care-service
#16
Erica C Kaye, Samantha DeMarsh, Courtney A Gushue, Jonathan Jerkins, April Sykes, Zhaohua Lu, Jennifer M Snaman, Lindsay J Blazin, Liza-Marie Johnson, Deena R Levine, R Ray Morrison, Justin N Baker
BACKGROUND: In the U.S., more children die from cancer than from any other disease, and more than one third die in the hospital setting. These data have been replicated even in subpopulations of children with cancer enrolled on a palliative care service. Children with cancer who die in high-acuity inpatient settings often experience suffering at the end of life, with increased psychosocial morbidities seen in their bereaved parents. Strategies to preemptively identify children with cancer who are more likely to die in high-acuity inpatient settings have not been explored...
May 4, 2018: Oncologist
https://www.readbyqxmd.com/read/29703766/immuno-oncology-biomarkers-for-gastric-and-gastroesophageal-junction-adenocarcinoma-why-pd-l1-testing-may-not-be-enough
#17
Benjamin A Weinberg, Joanne Xiu, Jimmy J Hwang, Anthony F Shields, Mohamed E Salem, John L Marshall
PURPOSE: The treatment of patients with advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas has been transformed by the U.S. Food and Drug Administration approval of pembrolizumab. Tumor and adjacent tissue must stain positively for the programmed cell death ligand 1 (PD-L1) protein by companion diagnostic testing. However, some patients with PD-L1-negative tumors also benefit from pembrolizumab. High microsatellite instability (MSI) and tumor mutational load (TML) are positive predictive biomarkers for immune checkpoint inhibition (ICI) in other tumors...
April 27, 2018: Oncologist
https://www.readbyqxmd.com/read/29703765/role-of-epidermal-growth-factor-receptor-egfr-inhibitors-and-radiation-in-the-management-of-brain-metastases-from-egfr-mutant-lung-cancers
#18
REVIEW
Melin J Khandekar, Zofia Piotrowska, Henning Willers, Lecia V Sequist
The growth of genotype-directed targeted therapies, such as inhibitors of the epidermal growth factor receptor (EGFR), has revolutionized treatment for some patients with oncogene-addicted lung cancer. However, as systemic control for these patients has improved, brain metastases remain an important source of morbidity and mortality. Traditional treatment for brain metastases has been radiotherapy, either whole-brain radiation or stereotactic radiosurgery. The growing availability of drugs that can cross the blood-brain barrier and have activity in the central nervous system (CNS) has led to many studies investigating whether targeted therapy can be used in combination with or in lieu of radiation...
April 27, 2018: Oncologist
https://www.readbyqxmd.com/read/29703764/emerging-gene-fusion-drivers-in-primary-and-metastatic-central-nervous-system-malignancies-a-review-of-available-evidence-for-systemic-targeted-therapies
#19
REVIEW
Priscilla K Brastianos, Franziska Maria Ippen, Umbreen Hafeez, Hui K Gan
Primary and metastatic tumors of the central nervous system present a difficult clinical challenge, and they are a common cause of disease progression and death. For most patients, treatment consists primarily of surgery and/or radiotherapy. In recent years, systemic therapies have become available or are under investigation for patients whose tumors are driven by specific genetic alterations, and some of these targeted treatments have been associated with dramatic improvements in extracranial and intracranial disease control and survival...
April 27, 2018: Oncologist
https://www.readbyqxmd.com/read/29700211/monoclonal-antibodies-and-multiple-myeloma-all-in-all-it-s-just-another-brick-in-the-wall
#20
Pellegrino Musto
No abstract text is available yet for this article.
April 26, 2018: Oncologist
journal
journal
20207
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"